These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24575583)

  • 41. Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.
    Sharvadze LG; Gogichaishvili ShSh; Sakandelidze TsG; Zhamutashvili MT; Chkhartishvili NI
    Georgian Med News; 2009 Jan; (166):61-4. PubMed ID: 19202222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection.
    Dalgard O; Martinot-Peignoux M; Verbaan H; Bjøro K; Ring-Larsen H; Marcellin P
    PLoS One; 2015; 10(8):e0120866. PubMed ID: 26317978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
    Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
    Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
    Marcellin P; Craxi A; Brandao-Mello CE; Di Bisceglie AM; Andreone P; Freilich B; Rajender Reddy K; Olveira Martín A; Teuber G; Messinger D; Hooper G; Wat C; Tatsch F; Jensen DM
    J Clin Gastroenterol; 2013 Oct; 47(9):786-93. PubMed ID: 23442834
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients.
    Matsuura K; Tanaka Y; Hasegawa I; Ohno T; Tokuda H; Kurbanov F; Sugauchi F; Nojiri S; Joh T; Mizokami M
    J Clin Microbiol; 2009 Feb; 47(2):385-9. PubMed ID: 19091819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
    Pattullo V; Ravindran NC; Mazzulli T; Wong DK; Heathcote EJ
    J Viral Hepat; 2010 Dec; 17(12):834-8. PubMed ID: 20196800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.
    Kumada H; Toyota J; Okanoue T; Chayama K; Tsubouchi H; Hayashi N
    J Hepatol; 2012 Jan; 56(1):78-84. PubMed ID: 21827730
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection.
    Halfon P; Pénaranda G; Bourlière M; Khiri H; Masseyeff MF; Ouzan D
    J Med Virol; 2006 Feb; 78(2):208-15. PubMed ID: 16372298
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.
    Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H
    J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Predicting sustained virological response in chronic hepatitis C patients treated with pegylated interferon and ribavirin using a novel highly sensitive Real-time detection PCR assay].
    Matsuura K; Tanaka Y; Takagi K; Hiramatsu K; Kani S; Gotoh T; Wakimoto Y; Joh T; Mizokami M
    Rinsho Byori; 2007 Nov; 55(11):983-8. PubMed ID: 18154028
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
    Kowdley KV; Lawitz E; Crespo I; Hassanein T; Davis MN; DeMicco M; Bernstein DE; Afdhal N; Vierling JM; Gordon SC; Anderson JK; Hyland RH; Dvory-Sobol H; An D; Hindes RG; Albanis E; Symonds WT; Berrey MM; Nelson DR; Jacobson IM
    Lancet; 2013 Jun; 381(9883):2100-7. PubMed ID: 23499440
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Nakano S; Arakawa T
    Liver Int; 2009 Jan; 29(1):120-5. PubMed ID: 18384519
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin.
    Andriulli A; Di Marco V; Margaglione M; Ippolito AM; Fattovich G; Smedile A; Valvano MR; Calvaruso V; Gioffreda D; Milella M; Morisco F; Felder M; Brancaccio G; Fasano M; Gatti P; Tundo P; Barone M; Cozzolongo R; Angelico M; D'Andrea G; Andriulli N; Abate ML; Mazzella G; Gaeta GB; Craxi A; Santantonio T
    J Hepatol; 2014 Jan; 60(1):16-21. PubMed ID: 23973930
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
    Fernández-Rodríguez CM; Morillas RM; Masnou H; Navarro JM; Bárcena R; González JM; Martín-Martín L; Poyato A; Miquel-Planas M; Jorquera F; Casanovas T; Salmerón J; Calleja JL; Solà R; Alonso S; Planas R; Romero-Gomez M
    Gastroenterol Hepatol; 2014 Jan; 37(1):1-8. PubMed ID: 24360571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis C].
    Kim MN; Yoon KT; Park JY; Kim DY; Ahn SH; Chon CY; Han KH
    Korean J Hepatol; 2009 Dec; 15(4):496-503. PubMed ID: 20037268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
    Morishima C; Morgan TR; Everhart JE; Wright EC; Shiffman ML; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Gretch DR;
    Hepatology; 2006 Aug; 44(2):360-7. PubMed ID: 16871570
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
    Ferenci P; Laferl H; Scherzer TM; Gschwantler M; Maieron A; Brunner H; Stauber R; Bischof M; Bauer B; Datz C; Löschenberger K; Formann E; Staufer K; Steindl-Munda P;
    Gastroenterology; 2008 Aug; 135(2):451-8. PubMed ID: 18503773
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.
    Marcellin P; Reau N; Ferenci P; Hadziyannis S; Messinger D; Tatsch F; Jensen D
    J Hepatol; 2012 Jun; 56(6):1276-82. PubMed ID: 22314423
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C.
    Arase Y; Suzuki F; Sezaki H; Suzuki Y; Kawamura Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Ikeda K; Kobayashi M; Kumada H
    Intern Med; 2008; 47(14):1301-7. PubMed ID: 18628577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.